DEFEROXAMINE (DESFERRIOXAMINE) - NEW TOXICITIES FOR AN OLD DRUG

被引：45

作者：

BENTUR, Y

MCGUIGAN, M

KOREN, G

机构：

[1] Israel Poison Information Center, Rambam Medical Center, Faculty of Medicine, Technion, Haifa

[2] Division of Clinical Pharmacology and Toxicology, Poison Information Center, The Hospital for Sick Children, Toronto, Ontario

来源：

DRUG SAFETY | 1991年 / 6卷 / 01期

关键词：

D O I：

10.2165/00002018-199106010-00004

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Iron is an essential element for body homoeostasis, but there is no effective mechanism for elimination of an excess of this mineral. Deferoxamine (desferrioxamine) is currently the treatment of choice for iron overload states from both acute iron intoxication and transfusion-dependent anaemias. The pharmacokinetics of deferoxamine are confounded both by its ability to chelate endogenous and exogenous iron and by the laboratory techniques used for its determination. Its iron-complex (ferrioxamine) has different pharmacokinetic properties. Because of its effectiveness, the use of deferoxamine is becoming more common, involving long term and high dose regimens. As a result of this, more and more toxicities that were not known in the past have been described and characterised. The most serious of these include hypotension, renal insufficiency, neurotoxicity, growth retardation and opportunistic infections; some of these side effects may be attributed to or aggravated by ferrioxamine. The pharmacological and toxicological literature on deferoxamine, and possible mechanisms for its toxicity, are reviewed and discussed.

引用

页码：37 / 46

页数：10

共 89 条

[1] Allain P., Mauras Y., Chaleil D., Et al., Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis, British Journal of Clinical Pharmacology, 24, pp. 207-212, (1987)
[2] Balcerzak S.P., Jensen W.N., Pollack S., Mechanism of action of desferrioxamine on iron absorption, Scandinavian Journal of Haematology, 3, pp. 205-212, (1966)
[3] Barker G.A., Brown T.C.K., Hosking C.S., Acute iron poisoning —clinical features and management, Anaesthesia and Intensive Care, 4, pp. 345-350, (1974)
[4] Batey R., Scott J., Jain S., Sherlock S., Acute renal insufficiency occurring during intravenous desferrioxamine therapy, Scandinavian Journal of Haematology, 22, pp. 277-279, (1979)
[5] Bene C., Manzler A., Bene D., Kranias G., Irreversible ocular toxicity from single ‘challenge’ dose of desferrioxamine, Clinical Nephrology, 31, pp. 45-48, (1989)
[6] Bentur Y., Koren G., Klein J., Tesoro A., Leeder J.S., Pharmacokinetics of deferoxamine with and without iron load, Veterinary and Human Toxicology, 31, pp. 156-157, (1989)
[7] Blake D.R., Winyard P., Lunec J., Et al., Cerebral and ocular toxicity induced by desferrioxamine, Quarterly Journal of Medicine, 56, pp. 345-355, (1985)
[8] Blatt J., Stitley S., Antineuroblastoma activity of desferioxamine in human cell lines, Cancer Research, 47, pp. 1749-1750, (1987)
[9] Bloomfield S.E., Markenson A.L., Miller D.R., Peterson C.M., Lens opacities in thalassemia, Journal of Pediatric Ophthalmology and Stabismus, 15, pp. 154-156, (1978)
[10] Borgna-Pignatti C., De Stefano P., Broglia A.M., Visual loss in patient on high-dose subcutaneous desferrioxamine, Lancet, 1, (1984)

← 1 2 3 4 5 6 7 8 9 →